Why Is Acne Medication So Expensive? The 2024 US Guideline Downgraded Two Drugs on Cost

American guidance puts topical treatment at the center of acne management. Aside from topical antibiotics, it can be used alone or in combination for both initial and maintenance therapy. Four topical retinoids are approved for acne in the US, and the guideline states plainly that none has been shown superior to the others.

The guideline's best sentence is the one already mentioned. Clascoterone and sarecycline stayed conditional, and the reason given wasn't a gap in the evidence. It was the currently high cost of treatment. What's best and what's affordable split apart inside a single American clinical document, in writing.

This is worth an editorial aside. Guidelines rarely name cost as the reason for a downgraded recommendation; usually the reason is evidence quality or side effects. This one names the price tag instead, and that choice says something about the system producing it.

The guideline also notes that non-retinoid topical treatment is preferred during pregnancy, but this article does not compile a list of what's safe or unsafe to use while pregnant. The sourcing hasn't been cross-checked closely enough, and that kind of call isn't one a blog should make anyway.

There is a separate part of the guideline addressing severe acne that doesn't respond to standard treatment. This article doesn't cover what that treatment is, how well it works, or who it's for. The safety literature around it hasn't been verified yet.

The Japanese Dermatological Association published its acne and rosacea treatment guideline in 2023. Minds, the clinical practice guideline library run by the Japan Council for Quality Health Care, selected it in March 2024. What stands out is that this single document covers both acne (尋常性痤瘡) and rosacea (酒皶), a pairing the American guideline doesn't make; the US treats the two as separate documents entirely.

The guideline is structured as a series of clinical questions, and the first three all concern combination products: a clindamycin and benzoyl peroxide gel, an adalapalene and benzoyl peroxide gel, and adalapalene gel used alongside a topical antimicrobial. That's the same direction as the American guideline's push toward fixed-dose combinations. Two dermatology societies, working independently, arrived at a similar answer.

The same Japanese association goes further on another condition, publishing an A-to-D recommendation grade for ten hair loss treatments, a table neither the US nor Korea matches: what has evidence behind it, graded and published.

The Japanese association added a caveat to its own public release that's worth quoting. It describes the guideline as an attempt to present "the most standard and best practice believed appropriate in our country," while noting that it "mainly assumes care provided by dermatologists, and may not necessarily apply to care by non-dermatologist physicians." A guideline narrowing its own scope in writing isn't something you see often.

Korea's Ministry of Food and Drug Safety runs a pregnancy-prevention program for retinoid-class medications, a drug category carrying teratogenic risk. The program has three pillars: doctors and pharmacists must explain the risk and contraception requirements before prescribing; a prescription can only be filled if the patient agrees to follow the contraception rules; and a prescription is only valid within 30 days of confirming the patient is not pregnant.

The required contraception period varies by ingredient, and for some it runs up to three years after the last dose. The agency has also required stronger warning text on packaging for this drug class and plans to expand pictogram warnings on products requiring caution during pregnancy. It asked the national health insurance review agency to help pharmacists and doctors confirm pregnancy status for every patient of reproductive age.

What Korea built here is not a standard for how well the drug works. It is a checklist of what must be said and confirmed before anyone can fill the prescription. This article doesn't cover the drug's efficacy or what it's used for, since the relevant safety literature hasn't been verified, and current insurance-coverage rules aren't covered either, since the only available data on that point is more than a decade old.